BiomX
Initial Transaction Details
Transaction Date
March 2024
Purpose of Financing
Stage of Company
Structure of Financing
BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets.
Original transaction with Adaptive Phage Therapeutics in May 2021.
Website